CN1231218C - 药物组合物在制备用于治疗中耳感染的药物中的用途 - Google Patents

药物组合物在制备用于治疗中耳感染的药物中的用途 Download PDF

Info

Publication number
CN1231218C
CN1231218C CNB028183002A CN02818300A CN1231218C CN 1231218 C CN1231218 C CN 1231218C CN B028183002 A CNB028183002 A CN B028183002A CN 02818300 A CN02818300 A CN 02818300A CN 1231218 C CN1231218 C CN 1231218C
Authority
CN
China
Prior art keywords
ciprodex
treatment
day
patient
floxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028183002A
Other languages
English (en)
Chinese (zh)
Other versions
CN1555267A (zh
Inventor
M·G·沃尔
P·J·康罗伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Pharmaceuticals Ltd
Novartis AG
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23261416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1231218(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of CN1555267A publication Critical patent/CN1555267A/zh
Application granted granted Critical
Publication of CN1231218C publication Critical patent/CN1231218C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB028183002A 2001-09-21 2002-09-13 药物组合物在制备用于治疗中耳感染的药物中的用途 Expired - Lifetime CN1231218C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32395101P 2001-09-21 2001-09-21
US60/323,951 2001-09-21

Publications (2)

Publication Number Publication Date
CN1555267A CN1555267A (zh) 2004-12-15
CN1231218C true CN1231218C (zh) 2005-12-14

Family

ID=23261416

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028183002A Expired - Lifetime CN1231218C (zh) 2001-09-21 2002-09-13 药物组合物在制备用于治疗中耳感染的药物中的用途

Country Status (19)

Country Link
US (8) US20030139382A1 (OSRAM)
EP (1) EP1429780B1 (OSRAM)
JP (1) JP2005504804A (OSRAM)
KR (1) KR20040035760A (OSRAM)
CN (1) CN1231218C (OSRAM)
AT (1) ATE313328T1 (OSRAM)
AU (1) AU2002333671B2 (OSRAM)
BR (1) BR0212898A (OSRAM)
CA (1) CA2459930C (OSRAM)
CY (1) CY1104988T1 (OSRAM)
DE (1) DE60208216T2 (OSRAM)
DK (1) DK1429780T3 (OSRAM)
ES (1) ES2250739T3 (OSRAM)
FR (1) FR13C0012I2 (OSRAM)
MX (1) MXPA04002576A (OSRAM)
PL (1) PL212457B1 (OSRAM)
RU (1) RU2295346C2 (OSRAM)
WO (1) WO2003026671A1 (OSRAM)
ZA (1) ZA200401847B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212898A (pt) * 2001-09-21 2004-10-13 Alcon Inc Método de tratamento de infecções do ouvido médio
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
PL1776109T3 (pl) * 2004-08-13 2009-06-30 Schering Plough Ltd Farmaceutyczna formulacja zawierająca antybiotyk, triazol i kortykosteroid
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20080139545A1 (en) * 2006-05-22 2008-06-12 Won-Taek Choe Formulation to treat ear infection
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
US8088095B2 (en) * 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
US20090263345A1 (en) * 2008-01-28 2009-10-22 Foresight Biotherapeutics, Inc. Otic compositions for the treatment of infections of the internal and external ear in mammals
WO2009139924A2 (en) 2008-05-14 2009-11-19 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8784790B2 (en) 2008-06-12 2014-07-22 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
BRPI0916323A2 (pt) * 2008-07-21 2018-05-29 Otonomy Inc composições antimicrobianas de liberação controlada e métodos para o tratamento de distúrbios do ouvido
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US20100086576A1 (en) * 2008-10-06 2010-04-08 Myntti Matthew F Antimicrobial composition and methods of making and using same
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
CN102340993A (zh) * 2009-03-03 2012-02-01 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
WO2010101989A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2440165A4 (en) * 2009-06-08 2014-01-22 Otic Pharma Ltd FOAM FORMULATIONS FOR THE EAR
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
US10653133B2 (en) 2011-05-10 2020-05-19 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
US9561240B2 (en) * 2012-12-26 2017-02-07 Otic Pharma Ltd. Foamable otic pharmaceutical compositions
WO2015031393A1 (en) 2013-08-27 2015-03-05 Otonomy, Inc. Treatment of pediatric otic disorders
US20150119371A1 (en) * 2013-10-30 2015-04-30 Micro Labs Limited Topical pharmaceutical compositions of antibiotics and steroidal anti inflammatory agents
CN106794144B (zh) 2014-07-03 2020-07-17 奥德纳米有限公司 环丙沙星组合物的灭菌
US9393243B1 (en) * 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
WO2018053173A1 (en) 2016-09-16 2018-03-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134718A (en) * 1963-12-12 1964-05-26 Schering Corp Pregna-1,4-dienes and compositions containing same
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US5223493A (en) * 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
DE3704907A1 (de) * 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
SU1811833A1 (ru) * 1989-06-09 1993-04-30 Vladimir I Ivanov Способ введения лекарственных средств в ухо 2
DE69224071T2 (de) * 1991-09-17 1998-05-07 Alcon Lab Inc Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen
ES2065846B1 (es) 1993-04-20 1995-10-01 Cusi Lab Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
ES2078175B1 (es) 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
ES2079320B1 (es) * 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
ES2173287T3 (es) 1995-06-06 2002-10-16 Bayer Ag Composiciones oticas antibacterianas no irritantes, no sensibilizantes y no ototoxicas.
DE19524691A1 (de) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
ES2106680B1 (es) * 1995-08-03 1998-07-01 Vita Invest Sa Composiciones acuosas conteniendo ciprofloxacino y utilizacion y procedimiento correspondientes.
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
AR020660A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
AU6275999A (en) 1998-09-30 2000-04-17 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
EP1214056B1 (en) * 1999-09-24 2003-10-29 Alcon Inc. Topical suspension formulations containing ciprofloxacin and dexamethasone
BR0212898A (pt) * 2001-09-21 2004-10-13 Alcon Inc Método de tratamento de infecções do ouvido médio

Also Published As

Publication number Publication date
KR20040035760A (ko) 2004-04-29
MXPA04002576A (es) 2004-06-18
CA2459930A1 (en) 2003-04-03
BR0212898A (pt) 2004-10-13
CN1555267A (zh) 2004-12-15
JP2005504804A (ja) 2005-02-17
US20050059674A1 (en) 2005-03-17
CY1104988T1 (el) 2009-11-04
RU2295346C2 (ru) 2007-03-20
US9345714B2 (en) 2016-05-24
US20140363511A1 (en) 2014-12-11
EP1429780B1 (en) 2005-12-21
DK1429780T3 (da) 2006-02-13
US8846650B2 (en) 2014-09-30
US20030139382A1 (en) 2003-07-24
AU2002333671B2 (en) 2006-07-20
US20160243029A1 (en) 2016-08-25
PL212457B1 (pl) 2012-10-31
US20160361324A1 (en) 2016-12-15
ES2250739T3 (es) 2006-04-16
US20090156566A1 (en) 2009-06-18
WO2003026671A1 (en) 2003-04-03
DE60208216T2 (de) 2006-06-29
US9402805B1 (en) 2016-08-02
ATE313328T1 (de) 2006-01-15
EP1429780A1 (en) 2004-06-23
ZA200401847B (en) 2005-05-25
US20080214513A1 (en) 2008-09-04
RU2004111984A (ru) 2005-02-27
DE60208216D1 (de) 2006-01-26
FR13C0012I1 (OSRAM) 2013-04-05
US9149486B2 (en) 2015-10-06
US20150374716A1 (en) 2015-12-31
FR13C0012I2 (fr) 2014-02-14
CA2459930C (en) 2009-11-10
PL369205A1 (en) 2005-04-18

Similar Documents

Publication Publication Date Title
US9402805B1 (en) Method of treating middle ear infections
AU2002333671A1 (en) Method of treating middle ear infections
US10632147B2 (en) Methods and compositions for treating inflammatory disorders
US9486405B2 (en) Methods for the treatment of pediatric otic disorders
Karale et al. An evaluation of antibacterial efficacy of 3% sodium hypochlorite, high-frequency alternating current and 2% chlorhexidine on Enterococcus faecalis: An: in vitro: study
Makandar et al. Triple antibiotic paste––Challenging intracanal medicament: A systematic review
da Mota et al. Evaluation of the effectiveness of photodynamic therapy for the endodontic treatment of primary teeth: study protocol for a randomized controlled clinical trial
Seigel et al. Chromobacterium violaceum necrotizing fasciitis: a case report and review of the literature
Takahashi et al. Efficacy and safety of 1.5% levofloxacin otic solution for the treatment of otitis media in a multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase III study
Burduk et al. Chronic, recurrent, progressive osteomyelitis of the maxilla caused by Methicillin-resistant Staphylococcus epidermidis: a therapeutic dilemma
Chitsazi et al. Effect of sterile tetracycline ophthalmic ointment as an adjuvant to mechanical debridement on the treatment of peri-implantitis: A randomized controlled clinical trial
Tanimoto et al. Multiple primary pleomorphic adenomas in a single parotid gland: report of a new case
Nyalazi et al. A Rare Case of Bilateral Post Intravitreal Avastin Endophthalmitis with Bilateral Good Visual Outcome–A Case Report
ES2369769T3 (es) Composiciones veterinarias para tratar la mastitis.
CN121129820A (zh) 一种含苯胺洛芬的耳用制剂组合物及其应用
Kakarmath et al. Comparative evaluation of the efficacy of 10% doxycycline gel and 1% chlorhexidine digluconate gel in the disinfection of sandblasted acid-etched titanium implant surface contaminated with Porphyromonas gingivalis
Pereira et al. Cochlear Implant Infection in a Teenager with CHARGE Syndrome: A Case Report
Kumar et al. Diagnostic Perspectives
Sangle et al. Administration of serratiopeptidase lead to increase in spread of space infection.
Thakali et al. Postoperative Endophthalmitis caused by Escherichia coli and Burkholderia cepacia complex: A Rare Case Report
CN115837008A (zh) 一种基于细胞穿膜肽的犬猫皮肤吸收的消炎凝胶
Al Jaouni et al. Research Article Effects of Honey on Oral Mucositis among Pediatric Cancer Patients Undergoing Chemo/Radiotherapy Treatment at King Abdulaziz University Hospital in Jeddah, Kingdom of Saudi Arabia
CN1909898A (zh) 滴眼剂组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200201

Address after: Fribourg

Patentee after: ALCON PHARMACEUTICALS LTD.

Address before: Basel, Switzerland

Patentee before: NOVARTIS AG

Effective date of registration: 20200201

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Hananberg, Switzerland

Patentee before: ALCON, Inc.

Effective date of registration: 20200201

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Fribourg

Patentee before: Alcon Pharmaceuticals Ltd.

TR01 Transfer of patent right
CX01 Expiry of patent term

Granted publication date: 20051214

CX01 Expiry of patent term